Compare STEX & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STEX | PBYI |
|---|---|---|
| Founded | 2009 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.8M | 263.4M |
| IPO Year | N/A | 2011 |
| Metric | STEX | PBYI |
|---|---|---|
| Price | $2.13 | $6.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $12.00 | $7.00 |
| AVG Volume (30 Days) | ★ 2.0M | 478.8K |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.61 |
| Revenue | N/A | ★ $27,685,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.93 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.98 | $2.58 |
| 52 Week High | $7.44 | $7.68 |
| Indicator | STEX | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 38.30 | 44.96 |
| Support Level | $2.04 | $5.57 |
| Resistance Level | $3.68 | $7.25 |
| Average True Range (ATR) | 0.21 | 0.45 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 23.45 | 32.80 |
Streamex Corp is a vertically integrated technology and infrastructure company. It is focused on the tokenization and digitalization of real-world assets. The group provides institutional-grade solutions that bring traditional commodities and assets on-chain through secure, regulated, and yield-bearing financial instruments. It is committed to delivering transparent, scalable, and compliant digital asset solutions that bridge the gap between traditional finance and blockchain-enabled markets.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.